Compare Annaly Capital Management, Inc. (NLY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs BIO-TECHNE Corp — how do they compare? Annaly Capital Management, Inc. trades at $18.41 (market cap $13.51B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Annaly Capital Management, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.73%). Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and BIO-TECHNE Corp for 63 Days on average.
| NLY | TECH | |
|---|---|---|
Market Cap | $13.51B | $11.37B |
Volume | 18,617,936 | 3,153,511 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $72.61 |
52-Week Low | $17.93 | $43.31 |
Typical Hold Time | 92 Days | 63 Days |
Enterprise Value | $135.54B | $11.40B |
Dividend Yield | 16.73% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.27, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The stock shows strong profitability with a 92.77% net income margin and 20.66% ROE, trading below book value at a P/B of 0.89. Recent earnings beats and a high 14.7% dividend yield attract income investors, though the stock faces pressure from rising mortgage rates and volatile cash flows.
The outlook is mixed: analyst consensus is bullish with a $22 price target, but technical weakness and interest rate sensitivity pose risks. The expanding MBS portfolio supports earnings growth, yet high leverage and macroeconomic headwinds require careful monitoring for dividend sustainability and capital appreciation potential.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
